Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical Company Limited announced that it has received approval from the National Medical Products Administration for a supplementary drug application, which involves the transfer of marketing authorization for the levalbuterol hydrochloride nebuliser solution. This approval follows a technology transfer agreement with Zhejiang Hengyan Pharmaceutical Technology Co., Ltd., allowing Xinhua Pharmaceutical to gain full rights and interests related to the product, enhancing its product portfolio and market presence.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production and sale of prescription drugs. The company is listed on the Hong Kong Stock Exchange, indicating its integration into international financial markets.
YTD Price Performance: -4.13%
Average Trading Volume: 3,098,188
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$9.09B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.
